Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemziviptadil in stable HFrEF and DMD-associated cardiac dysfunction
NCT02808585Phase 2Completed
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Jun 2016
- Primary completion
- Dec 2017
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of pemziviptadil in heart failure with reduced ejection fraction (HFrEF), Cardiac dysfunction, sponsored by PhaseBio Pharmaceuticals. Started Jun 2016; status: completed.
02
Drugs
pemziviptadil
03
Conditions
heart failure with reduced ejection fraction (HFrEF)Cardiac dysfunction
Beyond the preview
Go deeper on NCT02808585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808585.